Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Public Health ; 185: 290-297, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32712460

ABSTRACT

OBJECTIVES: Malnutrition is one of the leading causes of death among children younger than five years. In this study, we aimed to formulate a ready-to-use supplementary food (RUSF), based on local food products, and investigate its efficacy on growth indicators in children with mild to moderate malnutrition. STUDY DESIGN: This is a randomized controlled clinical trial. METHODS: This study was performed in six health centers in Shahr-e-Rey, Tehran, Iran, between April and October 2017. One hundred children, aged 24-59 months, with mild to moderate malnutrition (weight-for-height Z-score [WHZ] between -3 and -1) were randomly assigned to two groups to receive either 1-3 sachets of RUSF or normal diet for 8 weeks. All mothers and caregivers received nutrition education. Growth indicators including weight and height, WHZ, and body mass index (BMI), along with clinical outcomes, were assessed. RESULTS: Children who received RUSF had a significant increase in weight (1.44 ± 0.38 vs 0.7 ± 0.32 kg, respectively, P < 0.001), and BMI (1.2 ± 0.47 vs 0.35 ± 0.33 kg/m2, respectively, P < 0.001) compared with the control group. There was a greater daily weight gain during the first 4 weeks (P < 0.001) and throughout the study (P = 0.013) in the RUSF group. Daily height gain was considerably higher in the RUSF group during the first 4 weeks (P = 0.027). Children in the RUSF group had more improvement in WHZ (1.18 ± 0.41 vs 0.41 ± 0.31, P < 0.001) after supplementation. Besides, 92% of the RUSF and 12% of the control group reached to WHZ > -1 at the end of the study (P < 0.001). There was lower prevalence of diarrhea (12% vs 28.6%, respectively, P = 0.01) and marginally lower fever (16% vs 36.7%, respectively, P = 0.05) in the intervention than in the control group. CONCLUSIONS: A newly developed RUSF improved growth indicators and clinical outcomes in children with mild to moderate malnutrition. CLINICAL TRIAL REGISTRY NUMBER: IRCT2017021315536N6 (registered at www.irct.ir).


Subject(s)
Child Nutritional Physiological Phenomena , Dietary Supplements , Food, Formulated , Malnutrition/diet therapy , Body Mass Index , Body Weight , Child Development , Child, Preschool , Diet , Female , Humans , Iran , Male , Weight Gain
2.
Ir J Med Sci ; 186(1): 133-142, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27085343

ABSTRACT

BACKGROUND: Overweight and obesity has been suggested to be well correlated with altered levels of pro-inflammatory cytokines. AIM: The purpose of this study is to assess the relationship of body fat mass (BFM), body fat percentage (BFP) and leptin levels with peripheral blood mononuclear cells (PBMCs) cytokines among obese and overweight adults. METHODS: Eighty-two overweight and obese individuals were divided into two BMI-category groups (BMI <30 and BMI ≥30 kg/m2) in this study. Balanced blocked randomization was used based on their sex and BMI ranges. Fasting blood samples, PBMCs cytokines, leptin and anthropometric indices were measured and PBMCs were cultured. RESULTS: Mean of leptin concentrations were 23.14 ± 4.07 and 28.25 ± 4.35 pg/ml among individuals with BMI <30 and BMI ≥30 kg/m2, respectively. The mean values of anthropometric measurements (all P < 0.001), the concentrations of TNF-α (P = 0.028) and IFN-γ (P = 0.029) were significantly higher among obese individuals. BFP had a significant positive correlation with leptin (P < 0.001, r = 0.445) and TGF-ß (P = 0.03, r = 0.243). BFM has significant positive correlation with leptin (P < 0.001, r = 0.521). Leptin had a positive significant correlation with IFN-γ (p = 0.03, r = 0.251). CONCLUSIONS: Regarding these results, we proved that BFP, BFM and leptin levels have significant correlations with some PBMC cytokines. Focusing on such strategies may lead to promises for alleviating obesity and its co-morbidities.


Subject(s)
Leptin/blood , Leukocytes, Mononuclear/metabolism , Obesity/blood , Overweight/blood , Adipose Tissue , Adult , Body Mass Index , Cytokines/blood , Female , Humans , Male , Middle Aged , Tumor Necrosis Factor-alpha/blood
3.
Exp Clin Endocrinol Diabetes ; 125(3): 156-162, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27657997

ABSTRACT

Background: Adipolin, the novel adipokine that is proposed to be reduced in diabetes, obesity and inflammation, may improve glycemic control. It is known that coenzyme Q10 could improve insulin sensitivity. The aim of the current study was to investigate the effect of Q10 supplementation on adipolin concentration and glucose metabolism in overweight and obese diabetic patients. Material & Methods: Sixty four patients with type 2 diabetes and 25

Subject(s)
Adipokines/blood , Diabetes Mellitus, Type 2 , Obesity , Ubiquinone/analogs & derivatives , Adult , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Female , Glycated Hemoglobin/metabolism , Humans , Male , Middle Aged , Obesity/blood , Obesity/diet therapy , Ubiquinone/administration & dosage
4.
Horm Metab Res ; 49(2): 115-121, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27824398

ABSTRACT

Polycystic ovary syndrome (PCOS) is a heterogeneous, multi-causal, and genetically complex disorder, which is related to the failure in endocrine glands. Adiponectin has been reported to be low in PCOS, even in the absence of adiposity. Quercetin reduces serum glucose, insulin, triglycerides, and cholesterol levels and increases the expression and secretion of adiponectin. The aim of this study was to determine the effect of quercetin on the adiponectin-mediated insulin sensitivity in PCOS patients. Eighty-four women with PCOS were selected and randomly assigned to 2 groups of treatment and control. The treatment group received 1 g quercetin (two 500 mg capsules) daily for 12 weeks, and the control group received placebo. In addition to anthropometric assessments, fasting serum levels of total adiponectin, high-molecular-weight (HMW) adiponectin, glucose, insulin, testosterone, LH, and SHBG were also measured at the baseline and at the end of the trial. Quercetin could slightly increase the level of adiponectin by 5.56% as compared to placebo (adjusted p-value=0.001) and HMW adiponectin by 3.9% as compared to placebo (adjusted p-value=0.017), while it reduced the level of testosterone (0.71 ng/dl in quercetin vs. 0.77 ng/dl in placebo; p<0.001) and LH (8.42 IU/l in quercetin vs. 8.68 IU/l in placebo; p=0.009). HOMA-IR levels were also significantly (p<0.001) lower in quercetin (1.84) group compared to placebo group (2.21). Oral quercetin supplementation was effective in improving the adiponectin-mediated insulin resistance and hormonal profile of women with PCOS.


Subject(s)
Adiponectin/blood , Insulin/metabolism , Polycystic Ovary Syndrome/blood , Polycystic Ovary Syndrome/drug therapy , Quercetin/therapeutic use , Adult , Anthropometry , Double-Blind Method , Female , Humans , Molecular Weight , Placebos , Young Adult
5.
J Endocrinol Invest ; 39(8): 917-22, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27023106

ABSTRACT

AIM: To evaluate the relationship between inflammatory and pro inflammatory markers, with obesity and visceral adiposity in male subjects with or without metabolic syndrome (MS). SUBJECTS AND METHODS: A total of 37 patients with MS and 37 age matched controls were included (mean age 46.35 ± 1.6 years). MS was defined by the criteria of the international diabetes federation 2005. Anthropometric and biochemical profiles, including high-sensitivity C-reactive protein (Hs-CRP), visfatin and interleukin 6 (IL-6), were measured. Data were compared between groups by using t test. Pearson's correlation was used to evaluate the relationship between variables. P values less than 0.05 were considered as statistically significant. RESULTS: In patients with MS, CRP and IL-6 were significantly correlated with body mass index, waist circumference and waist to hip ratio. Visfatin levels were significantly lower in patients with MS compared to controls (log visfatin: 1.74 ± 0.27 vs. 1.86 ± 0.13 ng/ml, MS vs. control group respectively). We cannot find any significant correlation between visfatin, CRP and IL-6. Also there were no correlation between visfatin levels and any anthropometric parameters in patients with MS or control groups. CONCLUSION: Serum visfatin was lower in patients with MS. Therefore it seems that visfatin could not be considered as a pro inflammatory adipocytokine in MS. The positive associations of obesity and visceral adiposity with elevated CRP and IL-6 levels suggest the importance of reducing visceral adiposity to prevent the risk of coronary disease.


Subject(s)
Biomarkers/blood , C-Reactive Protein/metabolism , Interleukin-6/blood , Metabolic Syndrome/blood , Metabolic Syndrome/diagnosis , Nicotinamide Phosphoribosyltransferase/blood , Obesity/complications , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Humans , Inflammation Mediators/blood , Male , Metabolic Syndrome/etiology , Middle Aged
6.
Minerva Endocrinol ; 40(4): 259-66, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26140473

ABSTRACT

AIM: According to many studies, supplementation with Coenzyme Q10 (CoQ10) yields beneficial results in terms of endothelial function in type 2 diabetes mellitus. Despite these promising results, data elucidating the effect of CoQ10 on plasma levels of asymmetric dimethylarginine (ADMA), as a recently discussed cardiovascular risk factor, is lacking. This study was designed to investigate the effect of CoQ10 supplementation on endothelial function, specifically by evaluating plasma ADMA levels. METHODS: Sixty-four type 2 diabetic patients were randomly assigned to two groups; either receiving 200mg/d oral dose of CoQ10 (N.=31) or receiving placebo (N.=33) for 12 weeks. Clinical and biochemical assessments were performed before and after the trial for evaluating ADMA, serum nitrite and nitrate (NOx), hemoglobin A1c and lipid profile. RESULTS: The intervention resulted in a significant improvement in ADMA, NOx , low-density lipoprotein and hemoglobin A1c levels in CoQ10 compared to placebo group. Interestingly, difference in changes of these parameters were also significant (P=0.01, 0.03, 0.04 and 0.03, respectively). CONCLUSION: Supplementation with CoQ10 yields beneficial effects on ADMA levels, leading to decreased diabetic cardiovascular events.


Subject(s)
Antioxidants/therapeutic use , Arginine/analogs & derivatives , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Ubiquinone/analogs & derivatives , Adult , Aged , Arginine/blood , Blood Glucose/analysis , Dietary Supplements , Double-Blind Method , Female , Glycated Hemoglobin/analysis , Humans , Male , Middle Aged , Ubiquinone/therapeutic use
7.
Diabetes Metab Syndr ; 9(4): 320-3, 2015.
Article in English | MEDLINE | ID: mdl-25470626

ABSTRACT

BACKGROUND AND OBJECTIVES: There is evidence based studies which show that plasma level of visfatin and vaspin in patients with type 2 diabetes mellitus elevate in comparison with healthy people. But there is no consistency in plasma visfatin and vaspin concentration between studies done on obese people. For this reason, the aim of this study is to investigate the serum level concentrations of visfatin and vaspin in obese women compared to normal weight women. MATERIALS AND METHODS: The participants of this study consist of 43 women aged 20-50, and 43 healthy women with normal weight as a control group. They were matched for age and physical activity. 24h food recall was used to collect dietary information from subjects. Moreover, blood sampling was taken to measure the blood levels of sugar, lipid profile, vaspin and visfatin. RESULTS: The mean serum level of visfatin was not statistically different between obese and normal weight women. But, the obese women had statistically higher mean serum level of vaspin than normal women (p=0.04). We found no relations between serum levels of vaspin with serum concentration of visfatin. Also, serum levels of these two adipokines were not related to the serum concentrations of fasting glucose, total cholesterol, low-density lipoprotein cholesterol and triglyserides and high-density lipoprotein cholesterol. Also, there was a significant positive relationship between carbohydrate intake and serum visfatin level in women participating to this study (p=0.018, r=0.257). CONCLUSION: The results of this study demonstrated that the level of serum vaspin was significantly higher in obese women. But there were no differences in serum levels of visfatin in comparison to normal weight women. Meanwhile this study demonstrated a positive relationship between serum levels of visfatin with dietary intake of carbohydrate, but no relationship between serum level of visfatin and vaspin in women participating in this study.


Subject(s)
Biomarkers/blood , Cytokines/blood , Nicotinamide Phosphoribosyltransferase/blood , Obesity/blood , Serpins/blood , Adult , Body Mass Index , Case-Control Studies , Female , Follow-Up Studies , Humans , Insulin Resistance , Male , Middle Aged , Obesity/epidemiology , Prognosis , Risk Factors , Young Adult
8.
Minerva Gastroenterol Dietol ; 59(2): 231-6, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23831913

ABSTRACT

AIM: Increased oxidative stress and impaired antioxidant defense contribute to pathogenesis and progression of type 2 diabetes. Consistent with this fact, it has been shown that diabetic patients have reduced coenzyme Q10 level. In this study we sought to compare the effect of coenzyme Q10 versus placebo on glycemic control and lipid profile in type 2 diabetic patients. METHODS: In a randomized double-blind placebo-controlled trial, 64 type 2 diabetic patients were randomly assigned to receive either 200 mg Q10 or placebo daily for 12 weeks. Fasting blood samples were obtained and fasting plasma glucose (FPG), HbA1c, total cholesterol (TC), triglycerides (TG), LDL-C and HDL-C were measured. RESULTS: In this study no significant differences considering age, body mass index (BMI), diabetes duration, FPG, HbA1c, TC, TG, LDL-C and HDL-C were shown between two groups. Serum HbA1C concentration decreased in the Q10 treated group (8 ± 2.28 vs. 8.61 ± 2.47%) with no significant effect in the placebo group. Following intervention no differences have been shown regarding FPG, TG and HDL-C in Q10 treated group. Furthermore, mean differences of TC and LDL-C level were statistically altered between two groups (P value=0.027 and 0.039 respectively). CONCLUSION: In this study, Q10 treatment improved glycemic control, total and LDL cholesterol but these differences were associated with no favourable effects on TG and HDL-C.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Ubiquinone/analogs & derivatives , Double-Blind Method , Female , Humans , Male , Middle Aged , Ubiquinone/therapeutic use
9.
Minerva Endocrinol ; 34(4): 273-9, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20046156

ABSTRACT

AIM: We investigated the role of the -4689G/T promoter variant of the visfatin gene on serum visfatin concentration and biochemical markers in T2DM patient. METHODS: In a cross-sectional study we recruited 93 patients with type 2 diabetes. Laboratory and anthropometric measurements were included FBG, OGTT, HbA1C, lipid Profile, fasting serum visfatin, fasting serum insulin, weight, height, Body Mass Index (BMI) and waist hip ratio (WHR). Genotyping for visfatin gene was performed by using the PCR-RFLP method. RESULTS: Our findings showed significant differences in levels of low density lipoprotein (LDL) cholesterol, total cholesterol, high density lipoprotein (HDL) cholesterol and fasting serum insulin among various types of visfatin genotype (TT, GG, and GT). This study showed a significant correlation between circulating levels of visfatin and weight, BMI, hs-CRP and fasting insulin in TT genotype. But regarding GG genotype only fasting insulin had a significant correlation with circulating visfatin. CONCLUSIONS: Visfatin genotypes may account for insulin resistance and levels of lipid profile that may cause by different visfatin expression between genotypes.


Subject(s)
Cholesterol/blood , Cytokines/genetics , Diabetes Mellitus, Type 2/blood , Insulin Resistance/genetics , Nicotinamide Phosphoribosyltransferase/genetics , Aged , Body Mass Index , C-Reactive Protein/analysis , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cytokines/blood , Diabetes Mellitus, Type 2/genetics , Female , Genetic Predisposition to Disease , Genotype , Glucose Tolerance Test , Glycated Hemoglobin/analysis , Humans , Insulin/blood , Male , Middle Aged , Nicotinamide Phosphoribosyltransferase/blood
10.
Int J Obes (Lond) ; 32(12): 1807-15, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18982014

ABSTRACT

BACKGROUND: Chronically elevated interleukin-6 (IL-6) is implicated in obesity-associated pathologies, where a proportion of this cytokine is derived from adipose tissue. Proinflammatory prostaglandins, which regulate this cytokine elsewhere, are also produced by this tissue. OBJECTIVE: To investigate whether constitutively active cyclooxygenase (COX)/prostaglandin (PG) pathway in white adipose tissue (WAT) is responsible for basal IL-6 production. DESIGN: The effect of acetylsalicylic acid (ASA), an inhibitor of COX, on IL-6 was assessed in human subjects and mice. COX, downstream PG synthase (PGS) activity and PG receptor signalling were determined in subcutaneous (SC), gonadal (GN) WAT and adipocytes. METHODS AND RESULTS: In obese humans, low-dose ASA (150 mg day(-1) for 10 days) inhibited systemic IL-6 and reduced IL-6 release from SC WAT ex vivo (0.2 mM). Similarly, in mice, ASA (0.2 and 2.0 mg kg(-1)) suppressed SC WAT 6-keto-PGF(1alpha) (a stable metabolite of prostacyclin) and IL-6 release. Although both COX isoforms are comparably expressed, prostacyclin synthase expression is higher in GN WAT, with levels of activity correlating directly with IL-6. Both ASA (5 mM) and NS-398 (COX-2 selective inhibitor

Subject(s)
Adipose Tissue, White/metabolism , Aspirin/administration & dosage , Cyclooxygenase Inhibitors/administration & dosage , Interleukin-6/metabolism , Obesity/metabolism , Adipocytes/metabolism , Aged , Animals , Aspirin/pharmacology , Case-Control Studies , Cyclooxygenase Inhibitors/pharmacology , Female , Gonads/metabolism , Humans , Male , Mice , Mice, Obese , Middle Aged , Prostaglandin-Endoperoxide Synthases/metabolism , Receptors, Prostaglandin/metabolism , Subcutaneous Fat/metabolism , Tumor Necrosis Factor-alpha/blood
11.
Diabetologia ; 49(2): 394-7, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16397791

ABSTRACT

AIMS/HYPOTHESIS: Diets rich in n-3 polyunsaturated fatty acids, namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), protect against insulin resistance and obesity in rodents and increase insulin sensitivity in healthy humans. We tested whether the anti-diabetic effects of EPA and DHA involve enhanced production of the endogenous insulin sensitiser, adiponectin. METHODS: We studied the effects, in an obesity-promoting high-fat diet, of partial replacement of vegetable oils by EPA/DHA concentrate (6% EPA, 51% DHA) over a 5-week period in adult male C57BL/6J mice that either had free access to food or had their food intake restricted by 30%. At the end of the treatment, systemic markers of lipid and glucose metabolism and full-length adiponectin and leptin were measured. Adiponectin (Adipoq) and leptin (Lep) gene expression in dorsolumbar and epididymal white adipose tissue (WAT) and isolated adipocytes was quantified and adipokine production from WAT explants evaluated. RESULTS: In mice with free access to food, plasma triacylglycerols, NEFA, and insulin levels were lower in the presence of EPA/DHA, while glucose and leptin levels were not significantly altered. Food restriction decreased plasma triacylglycerols, glucose, insulin and leptin, but not adiponectin. EPA/DHA increased plasma adiponectin levels, independent of food intake, reflecting the stimulation of Adipoq expression in adipocytes and the release of adiponectin from WAT, particularly from epididymal fat. Expression of Lep and the release of leptin from WAT, while being extremely sensitive to caloric restriction, was unaltered by EPA/DHA. CONCLUSIONS/INTERPRETATION: Intake of diets rich in EPA and DHA leads to elevated systemic concentrations of adiponectin, largely independent of food intake or adiposity and explain, to some extent, their anti-diabetic effects.


Subject(s)
Adiponectin/biosynthesis , Adiponectin/genetics , Dietary Fats/pharmacology , Docosahexaenoic Acids/pharmacology , Eicosapentaenoic Acid/pharmacology , AMP-Activated Protein Kinase Kinases , Adipocytes/chemistry , Adipocytes/metabolism , Adiponectin/blood , Adipose Tissue/chemistry , Adipose Tissue/metabolism , Animals , Body Composition , Caloric Restriction , Dietary Fats/administration & dosage , Docosahexaenoic Acids/administration & dosage , Eating , Eicosapentaenoic Acid/administration & dosage , Enzyme Activation , Gene Expression Regulation , Glucose/metabolism , Insulin/blood , Insulin/physiology , Insulin Resistance , Leptin/analysis , Leptin/blood , Leptin/genetics , Leptin/physiology , Male , Mice , Mice, Inbred C57BL , Obesity/physiopathology , Obesity/prevention & control , Protein Kinases/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...